Hormonal
Omega-3 polyunsaturated fatty acids (EPA, DHA, DPA) exert anti-inflammatory and pro-resolving effects by being metabolized into specialized pro-resolving mediators (SPMs) such as resolvins, protectins, and maresins, which actively terminate inflammation and promote tissue regeneration rather than merely suppressing immune responses.
Consuming omega-3 fatty acids (EPA, DHA, DPA) supports the body's active resolution of inflammation through specialized mediators like resolvins and protectins. This process helps clear cellular debris, promotes tissue regeneration, and regulates immune responses, offering a pathway to manage chronic inflammatory states associated with diseases like cardiovascular issues and autoimmune disorders.
Many of the biological actions of PUFAs are mediated via bioactive lipid mediators produced by fatty acid oxygenases... Emerging evidence suggests that uncontrolled inflammation may contribute to a progression to chronic inflammatory states... Understanding the molecular mechanisms of how elevated omega-3 PUFA levels control inflammation and tissue homeostasis will lead to a new class of therapeutic applications.
Why this rating
The paper is a review citing numerous in vivo murine models and in vitro studies, establishing strong mechanistic evidence, though human clinical trial data is referenced less directly for specific dosing.
Source
Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis
Tomoaki Ishihara et al. · International Immunology · 2019
DOI 10.1093/intimm/dxz001
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →